Next Article in Journal
Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group
Next Article in Special Issue
Involvement of Long Non-Coding RNAs in Glucose Metabolism in Cancer
Previous Article in Journal
Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways
Previous Article in Special Issue
Functional Interaction among lncRNA HOTAIR and MicroRNAs in Cancer and Other Human Diseases

Argonaute Proteins Take Center Stage in Cancers

by 1,2 and 1,2,*
Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden
Author to whom correspondence should be addressed.
Academic Editor: Lyndsay Rhodes
Cancers 2021, 13(4), 788;
Received: 21 January 2021 / Revised: 9 February 2021 / Accepted: 10 February 2021 / Published: 13 February 2021
(This article belongs to the Collection The Role of Non-coding RNA in Cancer)
The dysregulation of RNA interference (RNAi) has often been observed in cancers, where the main focus of research has been on the small RNA molecules directing RNAi. In this review, we focus on the activity of Argonaute proteins, central components of RNAi, in tumorigenesis, and also highlight their potential applications in grading tumors and anti-cancer therapies.
Argonaute proteins (AGOs) play crucial roles in RNA-induced silencing complex (RISC) formation and activity. AGOs loaded with small RNA molecules (miRNA or siRNA) either catalyze endoribonucleolytic cleavage of target RNAs or recruit factors responsible for translational silencing and target destabilization. miRNAs are well characterized and broadly studied in tumorigenesis; nevertheless, the functions of the AGOs in cancers have lagged behind. Here, we discuss the current state of knowledge on the role of AGOs in tumorigenesis, highlighting canonical and non-canonical functions of AGOs in cancer cells, as well as the biomarker potential of AGO expression in different of tumor types. Furthermore, we point to the possible application of the AGOs in development of novel therapeutic approaches. View Full-Text
Keywords: Argonaute; miRNA; cancer; tumorigenesis; biomarker; therapeutics Argonaute; miRNA; cancer; tumorigenesis; biomarker; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Nowak, I.; Sarshad, A.A. Argonaute Proteins Take Center Stage in Cancers. Cancers 2021, 13, 788.

AMA Style

Nowak I, Sarshad AA. Argonaute Proteins Take Center Stage in Cancers. Cancers. 2021; 13(4):788.

Chicago/Turabian Style

Nowak, Iwona, and Aishe A. Sarshad. 2021. "Argonaute Proteins Take Center Stage in Cancers" Cancers 13, no. 4: 788.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop